Free Trial
LON:AVCT

Avacta Group (AVCT) Share Price, News & Analysis

Avacta Group logo
GBX 46.61 +2.36 (+5.33%)
(As of 11:52 AM ET)

About Avacta Group Stock (LON:AVCT)

Key Stats

Today's Range
44.28
46.61
50-Day Range
44.20
75.78
52-Week Range
39.63
143
Volume
3.09 million shs
Average Volume
2.36 million shs
Market Capitalization
£167.00 million
P/E Ratio
N/A
Dividend Yield
3.97%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Receive AVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

AVCT Stock News Headlines

Avacta Group Share Chat (AVCT)
“This Changes Everything” - Trump Hands Millions Massive IRS Gift
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
Avacta Group Plc (AVCTF)
See More Headlines

AVCT Stock Analysis - Frequently Asked Questions

Avacta Group's stock was trading at GBX 116.50 on January 1st, 2024. Since then, AVCT stock has decreased by 59.7% and is now trading at GBX 46.90.
View the best growth stocks for 2024 here
.

Avacta Group Plc (LON:AVCT) announced its quarterly earnings data on Monday, September, 28th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter. Avacta Group had a negative trailing twelve-month return on equity of 73.02% and a negative net margin of 114.45%.

Shares of AVCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avacta Group investors own include Legal & General Group (LGEN), Lloyds Banking Group (LLOY), Lloyds Banking Group (LYG), IQE (IQE), Barclays (BARC), Meta Platforms (META) and Revvity (PKI).

Company Calendar

Last Earnings
9/28/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

Net Income
£-25,890,000.00
Net Margins
-114.45%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£22.62 million
Cash Flow
GBX 3.13 per share
Book Value
GBX 14 per share

Miscellaneous

Free Float
N/A
Market Cap
£168.04 million
Optionable
Not Optionable
Beta
1.12
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (LON:AVCT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners